APIs are the therapeutic core of drugs, requiring strict compliance with USP/EP standards. Our patented purification technologies, such as low-endotoxin trehalose production, ensure high-purity APIs critical for vaccine stability and drug efficacy.
Pharmaceutical excipients like cellulose derivatives improve drug solubility, delivery, and stability in formulations, ensuring consistent performance across tablets, injections, and other dosage forms.
Intermediates (e.g., CDCA for UDCA synthesis) act as key precursors in API manufacturing. Biocatalytic processes streamline production, reducing costs and environmental impact while adhering to GMP regulations for safe, scalable drug development.
High-quality APIs and raw materials are the foundation of safe, effective drug production. Purity and Safety: Stringent standards (USP, EP, GMP) eliminate contaminants, preventing adverse reactions—critical for sensitive applications like vaccines (e.g., our low-endotoxin trehalose ensures stability). Efficacy Assurance: Precise molecular structure in APIs, supported by patented purification (e.g., amino acid chelation), guarantees consistent therapeutic outcomes. Regulatory Compliance: Global audits and certifications reduce recall risks and production delays, enabling market access in 50+ countries. Operational Efficiency: High-grade intermediates (e.g., CDCA for UDCA synthesis) streamline biocatalytic processes, cutting costs while minimizing environmental impact. Inadequate quality risks patient safety, regulatory penalties, and supply chain disruptions, making premium raw materials non-negotiable for reliable, scalable manufacturing.
